Evolus Inc. (Nasdaq: EOLS) appointed Lauren Silvernail as chief financial officer and executive vice president of corporate development. She joined Evolus from Revance Therapeutics (Nasdaq: RVNC), where she was most recently chief financial officer and chief business officer.
Irvine-based Evolus focuses on private-pay aesthetics treatments and procedures. Its first product is DWP-450, a purified botulinum toxin type A complex that’s awaiting Food and Drug Administration approval for the treatment of moderate to severe frown lines. The neurotoxin is designed to produce a result similar to Allergan plc’s Botox.
Like Evolus, Revance is focused on advancing its investigational product candidate, RT002, which has been shown to act similarly to Botox. The Newark-based biotechnology company is seeking both aesthetic and therapeutic indications.
Chief Executive David Moatazedi, who joined the company only last month, said Silvernail’s appointment “further strengthens our executive leadership team and represents a critical milestone for the company ahead of commercialization.”
